1xbet 사기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has received regulatory approval in Japan 1xbet 사기 the manufacture and sale of SAMTASU^®8mg and 16mg Intravenous Infusion 1xbet 사기 the treatment of cardiac edema.

SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted 1xbet 사기to an active drug 1xbet 사기 the human body follow1xbet 사기g adm1xbet 사기istration. Tolvaptan, discovered by Otsuka, is a novel compound that is as an antagonist of the vasopress1xbet 사기 V₂-receptor. It inhibits water reabsorption at the renal collecting duct, thereby enhancing water diuresis (aquaresis) without depletion of electrolytes. Until now, tolvaptan has been available only in oral 1xbet 사기m.

Outcomes from the phase 3 trial showed non-inferiority of SAMTASU versus tolvaptan 15 mg tablets in the trial primary endpoint, defined as change in body weight from baseline up until administration of the final dose. In addition, the main secondary endpoints also showed improvement comparable to that of tolvaptan in tablet 1xbet 사기m. No safety issues were identified during the trial.

SAMTASU is an intravenous diuretic that provides a new treatment option 1xbet 사기 patients with fluid retention who have difficulty receiving tolvaptan orally.